Mizuho Securities Believes AMGN Won’t Stop HereBy Jason Carr
Mizuho Securities analyst Salim Syed reiterated a Buy rating on Amgen Inc (NASDAQ: AMGN) today and set a price target of $195. The company’s shares opened today at $178.05, close to its 52-week high of $180.53.
According to TipRanks.com, Syed is a 3-star analyst with an average return of 8.4% and a 85.7% success rate. Syed covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Biogen Inc, and Celgene.
Currently, the analyst consensus on Amgen Inc is Strong Buy and the average price target is $197.57, representing a 11.0% upside.
In a report issued on February 28, Oppenheimer also reiterated a Buy rating on the stock with a $189 price target.
Amgen Inc’s market cap is currently $131.2B and has a P/E ratio of 17.36. The company has a book value ratio of 4.3917.
Based on the recent corporate insider activity of 88 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2016, Madhavan Balachandran, the EVP, Operations of AMGN sold 30,000 shares for a total of $4,623,600.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.